

view [Noxopharm Ltd](#) (ASX:NOX)

Noxopharm's Veyonda® may offer other therapeutic opportunities in chronic inflammatory and autoimmune diseases

The discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-value drug target for the company's subsidiary Pharmorage's emerging pipeline.

[Deep dive](#)



Rachel Middleton

16:25 Mon 23 Aug 2021



TBK1 also is the subject of considerable big pharma attention because of its potential involvement in autoimmune diseases.



[Noxopharm Ltd](#) (ASX:NOX) has discovered Veyonda®'s active ingredient idronoxil has an anti-inflammatory mechanism of action that provides a major opportunity to develop TANK-binding kinase 1 (TBK1) inhibitors for the treatment of autoimmune diseases.

The discovery further reinforces the relevance of Veyonda as a preventive treatment for cytokine storms driven by RNA virus infections, including COVID-19, and makes Veyonda the first TBK1 inhibitor to be tested in the clinic.

TBK1 adds a high-profile and potentially high-value drug target for the company's subsidiary Pharmorage's emerging pipeline.

Applications in other diseases

Its partnership with Hudson Institute of Medical Research has also led to the important discovery about the anti-inflammatory mechanism of action of idronoxil - TBK1, as the molecular target of idronoxil in terms of its anti-inflammatory properties.

The discovery is not yet peer-reviewed in a scientific publication but submission is anticipated in two months.

TBK1 has been proposed as a potential drug target in blocking COVID-19 disease progression, including the development of long-lasting COVID-19 symptoms.

However, beyond COVID-19, TBK1 also is the subject of considerable big pharma attention because of its potential involvement in autoimmune diseases



[Noxopharm set for busy six months ahead with strong news flow expected...](#)

Most read

Mining

[Core Lithium sets scene to become Australian's next lithium producer with...](#)

on 26/7/21

Mining

[Legend Mining begins regional exploration at Rockford project](#)

3 days, 5 hours ago

Mining

[Arafura Resources focuses on Final Investment Decision in](#)



3 MIN READ

[Prev article](#)

[Next article](#)

Privacy

[Noxopharm set for busy six months ahead with strong news flow expected from drug pipeline](#)

[read more >](#)

- > A potential use in blocking inappropriate inflammation to respiratory RNA viruses other than coronaviruses, including influenza viruses and respiratory syncytial virus; and
- > The creation of potential new therapeutic opportunities in the areas of chronic inflammatory and autoimmune diseases for Noxopharm subsidiary, Pharmorage, in partnership with Hudson.

First TBK1 inhibitor to be tested in clinic

Noxopharm group chief scientific officer Dr Olivier Laczka said: “This discovery, which is the result of a great collaborative effort between Noxopharm and experts in the field, further reinforces the relevance of Veyonda as a preventive treatment for cytokine storms driven by RNA virus infections, as is the case with COVID-19, and this to our knowledge makes Veyonda the first TBK1 inhibitor to be tested in the clinic.

“Pharmorage also is set to benefit considerably from this discovery.

“With a focus on new generation treatments for inflammatory conditions and autoimmune diseases, TBK1 adds a high-profile and potentially high-value drug target for Pharmorage’s emerging pipeline.”

Noxopharm to expand NOXCOVID program following posi



Long COVID-19 symptoms

Hudson Institute’s associate Professor Michael Gantier, Head of the Nucleic Acids and Innate Immunity Laboratory, said: “TBK1 is a point of convergence of many inflammatory pathways, and a target under significant investigation by several big pharmaceutical companies.

“Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation.

“Critically, TBK1 also directly controls production of interferon-beta, a cytokine associated with long-COVID symptoms.

1 week ago

Tech

Archer Materials’ deep tech could be game-changing for two key tech sectors

2 weeks, 2 days ago

Sponsored Financial Content



Why 2021 is Setting Up to Be a ‘Stock Picker’s Valhalla’
Money Morning



Top 3 ASX Mining Stocks
ThinkMarkets



US GDP: Measuring the health of an economy
eToro



3 Free Dividend Stock Picks
Motley Fool



3 Equity ETFs To Build Your Portfolio On
Morningstar

dianomi



3 MIN READ

[Prev article](#)

[Next article](#)

Privacy

“This suggests that idronoxil may not only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients.”

TBK1

TBK1 is a key protein in cells through which immune and inflammation signals pass in response to the detection of viruses and cancer.

TBK1 has become the subject of considerable industry attention because it could control a form of immune dysregulation that has been incriminated in the development of autoimmune diseases such as rheumatoid arthritis, lupus and motor neuron disease.

Quick facts: Noxopharm Ltd

Follow 

ASX:NOX | **Price:** 0.57 AUD | **Market Cap:** \$164.29 m [Show chart](#)

[View company profile](#)

Add related topics to MyProactive

[+ Health](#)

[+ Pharma & Biotech](#)

[+ Small caps](#)

[+ Noxopharm Ltd](#)

Email address

Sign up for Newsletter

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions,...

[FOR OUR FULL DISCLAIMER CLICK HERE](#)

Sponsored Financial Content




3 MIN READ


[Prev article](#)

[Next article](#)

[Privacy](#)



More on this story >



Health

Noxopharm to expand NOXCOVID program following positive phase 1...

2 days, 4 hours ago



Health

Noxopharm to expand NOXCOVID clinical program after "highly..."

3 days, 1 hour ago



Health

Noxopharm CEO highlights investment proposition at Proactive...

1 week, 6 days ago



Health

Noxopharm provides further information on National Cancer...

2 weeks, 1 day ago

Watch >



3 MIN READ

[Prev article](#)

[Next article](#)

Privacy



13.30



Noxopharm to expand NOXCOVID program following positive phase 1 results

Noxopharm Ltd (ASX:NOX)'s Graham Kelly tells Proactive they're planning to expand its NOXCOVID clinical program after receiving positive preliminary top-line data from its Phase 1 clinical trial for patients with coronavirus. The company's positioning Veyonda (idronoxil) as an anti-inflammatory...

2 days, 4 hours ago



17.33



Health

Noxopharm CEO highlights investment proposition at Proactive...

1 week, 6 days ago



07.40



Health

Noxopharm's Dr Graham Kelly outlines its four pillars oncology...

on 20/5/21



3 MIN READ


[Prev article](#)

[Next article](#)

Privacy



Editor's picks



Mining

Perseus Mining increases net profit by 48% in FY2021 to \$139...

5 hours, 17 minutes ago

Mining

Matador Mining produces further strong evidence of Cape Ray's...

5 hours, 29 minutes ago

Tech

archTIS boosts full-year revenue by 743% to \$4.6 million

6 hours, 7 minutes ago



3 MIN READ

[Prev article](#)

[Next article](#) **Privacy**